Blending fantasy and science fiction, N.E. Davenport’s fast-paced, action-packed debut kicks off a duology on loyalty and rebellion, in which a young Black woman must survive deadly trials in a racist and misogynistic society to become an elite warrior. Perfect for fans of RED RISING and AURORA RISING

Blending fantasy and science fiction, N. E. Davenport’s fast-paced, action-packed debut kicks off a duology of loyalty and rebellion, in which a young Black woman must survive deadly trials in a racist and misogynistic society to become an elite warrior. It’s all about blood. The blood spilled between the Republic of Mareen and the armies of the Blood Emperor long ago. The blood gifts of Mareen’s deadliest enemies. The blood that runs through the elite War Houses of Mareen, the rulers of the Tribunal dedicated to keeping the republic alive. The blood of the former Legatus, Verne Amari, murdered. For his granddaughter, Ikenna, the only thing steady in her life was the man who had saved Mareen. The man who had trained her in secret, not just in martial skills, but in harnessing the blood gift that coursed through her. Who trained her to keep that a secret. But now there are too many secrets, and with her grandfather assassinated, Ikenna knows two things: that only someone on the Tribunal could have ordered his death, and that only a Praetorian Guard could have carried out that order. Bent on revenge as much as discovering the truth, Ikenna pledges herself to the Praetorian Trials—a brutal initiation that only a quarter of the aspirants survive. She subjects herself to the racism directed against her half-Khanaian heritage and the misogyny of a society that cherishes progeny over prodigy, all while hiding a power that—if found out—would subject her to execution…or worse. Ikenna is willing to risk it all because she needs to find out who murdered her grandfather…and then she needs to kill them. Mareen has been at peace for a long time… Ikenna joining the Praetorians is about to change all that. Magic and technology converge in the first part of this stunning debut duology, where loyalty to oneself—and one’s blood—is more important than anything.

She’s spent her life trying not to become the monster they think she is…But what if a monster is exactly what they need? Injured and hunted, Jade is forced to flee the Northwind Pack’s territory and leave her mate, Darren Power, behind. But she’s been followed, and a hunter has his sights set on Jade, and he isn’t afraid to hurt those she loves to get to her. Finding herself backed into a corner, Jade is left with two options–run to draw the danger away from her friends or accept the help of her sworn enemy–for a price. What Jade doesn’t know is that Darren knows she’s in danger, and he won’t rest until she’s safe. But the rogues aren’t the only ones that call the mountain forests their home, and Darren is far from prepared for the dangers he’ll face on his quest to find Jade and right his father’s mistakes. Hunters, witches, betrayal, and forgotten legends are around every corner, and Darren and Jade are about to learn that the truth isn’t always what it seems. Can they let go of their pasts and what they know to find the truth before it’s too late? Blood Trials is the second book in The Blood Wolf Trilogy, a YA paranormal romance

Although the battle for Earth’s balance teeters on a precipice, Maysun, a powerful entity who maintains the world’s Balance, has stepped down from her role and blessed her lover, Eoghan, with her power. Days later, she realizes she may have made her decision much too soon. Charles Dunning, the head of the criminal global vampire tribe the Shévet ha Dam, is on the trail of Maysun’s only child, Amara. Amara lives half of her life awake and in fear, the other half in a shadowy world hardly remembered. She holds a power that allows her to resist the vampire curse, but only a select handful know of her ability. Even Amara is unaware of her gift. She believes she teeters on the edge of insanity, taunted by voices that have haunted her for years. She has no idea the voices are vampires trailing her every move. With Dunning determined to overrun the world with the Maleficence, his opponent, Vivian Black, must use the Source to find Amara first. With the help of new friends wielding unusual talents, Vivian and her family once again find themselves caught up in the global fight to ensure the world remains in equilibrium before Charles overruns it with darkness.

In a world of Angels, Demons, Vampires, Shifters, and Magic, Alec, a regular mortal is thrust into a world that's been hidden to every race but Witches.With nothing more than his wits and an old book, Alec volunteers himself to help Celadon, a stranger he found injured in an alley, complete her Blood Trials. The three trials set Alec and Cel on a mission of death, secrets, and blood.Will they make it out alive or fall victim to whoever has the hidden agenda of the missions they've been set on?

In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.